By proceeding, you agree to our Terms of Use and Privacy Policy.
The CDMO segment of the world's leading biotech company GenScript.
11-13 October 2022
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.
Event Ended
Hybrid
Paid
Carlsbad
10-13 April 2023
Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting op
San Diego
07-08 August 2023
Great progress has been made in studying cancer immunology and the development of immunotherapies. The complexity of the immune system and the duplicity of cancer, plus the expense of treatments and variable patient responses, make for a perfect data
USA
Boston
Cell therapies such as CAR Ts are now a proven treatment approach for hematological cancers, but challenges remain around CAR T’s ability to target solid tumors. Cambridge Healthtech Institute’s Tenth Annual Advances in CAR T Therapy conference bring
Bispecific antibodies are generating increased excitement for their potential to effectively target complex diseases through a dual-engagement approach. There are many new and powerful breakthroughs with bispecific antibodies relating to fine tuning
08-09 August 2023
Advances in harnessing the immune system for therapeutic development have resulted in a robust pipeline of immuno-oncology therapies and novel combinations. A successful program requires appropriate models and tools for preclinical evaluation and eff
Up until now, the cell therapy industry has been driven by the remarkable success of CAR T therapy. However, many believe the future of immunotherapy lies with other cell types such as NKs, Gamma Deltas, B Cells, TILs, and B cells, which offer many a
In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference
14-14 August 2023
Identifying, acquiring and retaining the right talent is complicated, especially in today’s increasingly competitive and complex biopharma market. The exponential growth of the biopharmaceutical industry combined with the growing shortfall of experie
14-15 August 2023
Advances in host cell engineering, better expression of cell lines and optimization of cell culture processes, have greatly accelerated upstream processing in the last decade, resulting in today's antibody production yield of 10g/L or more. Meanwhile
Vaccines and mRNA-based vaccines have recently gained a lot of attention due to COVID-19. Cambridge Healthtech Institute’s 3rd Annual Vaccine Development and Manufacturing conference tackles the practical challenges facing the development, manufactur
Cambridge Healthtech Institute’s Gene Therapy CMC and Analytics conference uncovers the practical challenges facing the analysis, characterization, and quality of viral vector-based gene therapies for clinical and commercial supply, with dedicated se
The popular 11th Annual Rapid Methods to Assess Stability and Impurities in Biologics conference will bring together experts in formulation, analytical sciences, and process to discuss rapid and practical ways to accelerate prediction and screening f
Cambridge Healthtech Institute’s Cell Therapy CMC and Analytics conference focuses on the characterization, control, and quality of cell-based therapies, supported by in-depth case studies and insight from leading industry and academic representative
The biopharma industry is driven by the need to increase productivity, reduce cost, while maintaining product quality and consistency. Continuous biomanufacturing and process intensification are borne out of such need. CHI’s Intensified & Continuous
Characterizing and controlling process-related impurities, such as host cell proteins (HCPs), is a critical part of bioprocessing, with regulators now pressing companies for more data and questions emerging on the role of HCPs in emerging modalities.
14-17 August 2023
The Bioprocessing Summit 2023, now in its fifteenth year, stands as the premier global forum for industry leaders to converge and exchange groundbreaking advancements in bioprocess research and development, scale-up, quality, and analytics. This high
16-17 August 2023
The approval of COVID-19 vaccines was the breakthrough for mRNA-based technology, and it opened so many opportunities for mRNA-based vaccines and therapeutics. CHI’s 2nd Annual mRNA-Based Therapies conference will explore the technical challenges fac
Pharmaceutical companies today are increasingly harnessing the power of digitalization to drive scientific and operational excellence across the value chain, from R&D to manufacturing. Digitalization is a key enabler to smarter bioprocessing and to h
Industry analytical groups are facing increased pressure to deliver key studies faster than ever before – and at lower costs. Cambridge Healthtech Institute’s 10th Annual Accelerating Analytical Development conference offers a best practices forum in
Newer and more complex molecules coming down the pipeline are bringing a new set of challenges to the downstream process development team, leading to the search for innovative technologies to meet the demand for higher yield while maintaining product
The development of high-concentration protein formulations for traditional and novel biologic products can be challenging during manufacturing, storage, and delivery due to problems such as aggregation, precipitation, gelation, and high viscosity. Th
Cambridge Healthtech Institute’s Gene Therapy Manufacturing conference discusses the practical challenges facing the production, purification, and manufacturing of viral and non-vector-based gene therapies. Topics include: AAV and lentivirus upstream
CHI’s Cell Therapy Manufacturing conference examines the practical challenges in manufacturing autologous and allogenic cell therapies at scale, with dedicated sessions on cell processing, scalability, next-generation production technologies, automat
18-21 September 2023
Join us at the Cell & Gene Therapy Manufacturing & Commercialization US 2023, the premier event dedicated to revolutionizing the field of cell and gene therapy manufacturing, commercialization, and supply chain strategies. As the leading conference i
The Largest Bioprocessing Event is an annual conference held at the Boston Convention and Exhibition Center, focusing on accelerating the development and commercial success of promising biologics, cell therapies, and gene therapies. The event brings
25-25 September 2023
The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod
Washington, DC
There has been growing interest in targeting kinases such as JAK, TYK, IRAK, SIK, CDK, MEK, ERK, RTK, PLK, PI3K, ALK, MAPK, GSK, LRRK, and more for their role in neurodegeneration, inflammation, cancer, autoimmune, and other disorders. However, targe
25-28 September 2023
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
26-27 September 2023
Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove
While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c
Cambridge Healthtech Institute's GPCR-Based Drug Discovery conference is now in its 18th year. G protein-coupled receptors (GPCRs), because of their central role in so many cellular processes, are still among the largest class of molecules modulated
Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules
As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern
A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are
Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especial
27-28 September 2023
Cambridge Healthtech Institute’s annual Lead Generation Strategies conference illuminates the latest approaches used by medicinal, biophysical and computational chemists to discover and develop small molecules (and now slightly larger molecules that
Fibrosis can be viewed as the end-stage of chronic inflammation. Fibrosis and inflammation are related to the immune system gone awry and both underlie many conditions related to aging and therefore are increasing in prevalence in the US. Cambridge H
Transcription factors are proteins with DNA-binding domains that are involved in gene transcription. They are key cell regulators and alterations in their structure, binding, or activity are often found associated with many abnormalities in cellular